PUFA salt formulations (I)

Abstract

The present patent application relates to novel polyunsaturated fatty acid salt (PUFA salts) solid formulations.

Claims

1. A particulate solid formulation comprising: (i) at least one polyunsaturated fatty acid (PUFA) salt, and (ii) 10-75 wt. % of a casein phosphopeptide.

2. The particulate solid formulation according to claim 1, wherein particles of the solid formulation have an average particle size (Dv50) of 10-200 m.

3. The particulate solid formulation according to claim 1, wherein particles of the solid formulation have an average particle size (Dv50) of 200-1000 m.

4. The particulate solid formulation according to claim 1, wherein particles of the solid formulation have an average particle size (Dv50) of more than 1000 m.

5. The particulate solid formulation according to claim 1, wherein the PUFA salt comprises at least one PUFA salt selected from the group consisting of PUFA sodium salts, PUFA potassium salts, PUFA magnesium salts and PUFA calcium salts.

6. The particulate solid formulation according to claim 1, wherein the at least one PUFA salt is selected from the group consisting of sodium, potassium and/or calcium salts of linoleic acid, arachidonic acid, -linolenic acid, dihomo--linolenic acid, -linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid.

7. The particulate solid formulation according to claim 1, wherein the solid formulation comprises 5-80 wt. %, based on total weight of the solid formulation, of the at least one PUFA salt.

8. The particulate solid formulation according to claim 1, wherein the solid formulation comprises up to 30 wt. %, based on total weight of the solid formulation, of at least one gum.

9. The particulate solid formulation according to claim 1, wherein the solid formulation comprises up to 30 wt. %, based on total weight of the solid formulation, of at least one sugar alcohol.

10. The particulate solid formulation according to claim 1, wherein the solid formulation comprises at least one auxiliary agent selected from the group consisting of antioxidants, plasticisers, stabilisers, humectants, protective colloids, dyes, fragrances, fillers and buffers.

11. The particulate solid formulation according to claim 10, wherein the antioxidant is at least one selected from the groups consisting of ascorbic acid or salts thereof, synthetic tocopherol, natural tocopherol, butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate; tert. butyl hydroxyquinoline and ascorbic acid esters of a fatty acid and ethoxyquin.

12. The particulate solid formulation according to claim 10, wherein the humectant is at least one selected from the group consisting of glycerine, sorbitol and polyethylene glycol.

13. A process for production of the particulate solid formulation of claim 1, wherein the process comprises: (i) dry mixing water soluble matrix ingredients to form a dry matrix mix, (ii) dissolving the dry matrix mix in water to form an aqueous matrix solution; (iii) adding the at least one PUFA salt to the aqueous matrix solution to form an aqueous mixture of the at least on PUFA salt and the matrix solution; and thereafter (iv) spray drying the aqueous mixture of the at least on PUFA salt and the matrix solution to form the particles of the solid formulation.

14. Food products, feed products, dietary supplements, pharmaceutical products and/or premixes, comprising the at least one solid formulation according to claim 1.

Description

EXAMPLE 1

(1) 25 g of maltodextrin (maltodextrin 28-31), 20 g of sodium ascorbate and 80 g of casein phosphopeptide (Hyvital Casein Phosphopetide from FrieslandCampina Domo) were put (in their dry state) into a beaker and mixed well.

(2) Afterward 800 g of water were added slowly to this mixture under constant stirring. This solution was heated up to 50 C., and adjust the pH was adjusted (by NaOH or KOH) to 8.5.

(3) The PUFA salt (the Na salt of MEG-3 4030 EE Oil) was also heated up to 50 C. and then the warm PUFA salt was added to the aqueous solution. A slurry way obtained.

(4) The so obtained slurry was spray dried (using a GEA MOBILE MINOR), inlet temperature was set at 150180 C., outlet temperature was controlled around 6080 C.

(5) A free-flowing powder was obtained.

(6) Testing of the Solid Formulations

(7) The storage stability of the produced solid formulations was tested as follows:

(8) The solid formulations were stored at room temperature and after defined storage times the formulations were evaluated by a sensory panel of experienced and well-trained persons.

(9) Each person of this panel sniffed at the solid formulations and gave them a value of the sensory scale.

(10) This sensory scale, which was applied, has values that goes from 0 to 15. 0 means no smell 15 means extremely strong.

(11) The following compositions are tested (the amount of the ingredients is given in gram (g)):

(12) TABLE-US-00001 TABLE 1 Formulations (1-4). The formulation 1 is the one produced as in Example 1. The forms 2-4 are comparative examples produced according to the method of example 1. Ingredients Form 1 Form 2 Form 3 Form 4 PUFA Na Salt of MEG-3 250 250 250 250 4030 EE Oil Maltodextrin 28-31 25 25 25 25 Sodium Ascorbate 15 15 15 15 Casein Phosphopeptide 80 Gelatin Rousselot 175 80 Whey Protein Concentrate 80 Egg Yolk 80 Water 1000 1000 1000 1000

(13) Form 1 is the inventive formulation. The Forms 2, 3, and 4 are comparative examples using other (commonly used) matrix materials

(14) Sensory Results:

(15) TABLE-US-00002 TABLE 2 the sensory results of the forms 1-4 Fishy Marine Complex Other off FORM 1 initial 4 weeks 8 weeks 12 weeks 1.0 16 weeks 20 weeks FORM 2 initial 4.0 4 weeks 4.0 8 weeks 5.0 FORM 3 initial 2.5 4 weeks 3.0 8 weeks 3.0 FORM 4 initial 5.0 4 weeks 2.0 8 weeks 3.0

(16) The formulations using other matrix materials are showing an unpleasant smell (fishy smell) right from the start!

(17) Formulations 5 and 6:

(18) The formulations are produced in accordance with the process as disclosed in Example 1.

(19) TABLE-US-00003 TABLE 3 formulations 5 and 6 Ingredients Form 5 Form 6 PUFA K Salt of MEG-3 4421 250 250 EE Oil Maltodextrin 28-31 25 25 Sodium Ascorbate 20 20 Casein Phosphopeptide 80 50 TIC Pretested Gum Arabic 30 Spray Dry Powder - Grade #1 Water 1000 1000

(20) These two forms (Form 5 and Form 6) are solid formulations according to the invention.

(21) Sensory Results

(22) TABLE-US-00004 TABLE 4 sensory results of formulations 5 and 6 Fishy Marine Complex Other Off FORM 5 initial 1.0 4 weeks 0.5 8 weeks 2 12 weeks 16 weeks 20 weeks 1 24 weeks 36 weeks 0.8 FORM 6 initial 1.0 4 weeks 0.5 8 weeks 12 weeks 16 weeks 1 20 weeks 1.0 1 24 weeks 2.0 36 weeks 1.5

(23) Formulations 7 and 8:

(24) TABLE-US-00005 TABLE 5 formulations 7 and 8 Ingredient Form 7 Form 8 PUFA Na Salt of MEG-3 4421 250 250 EE Oil Maltodextrin 28-31 25 25 Sodium Ascorbate 20 20 Casein Phosphopeptide 25 25 TIC Pretested Gum Arabic 30 30 Spray Dry Powder - Grade #1 Mannitol 25 Maltitol 25 Water 1000 1000

(25) Sensory Results

(26) TABLE-US-00006 TABLE 6 sensory results of formulations 7 and 8 Fishy Marine Complex Other Off Form 7 initial 1 4 weeks 1.3 8 weeks 12 weeks 0.8 16 weeks 2.0 20 weeks 1.5 1.5 End Form 8 initial 4 weeks 8 weeks 12 weeks 2.0 16 weeks 20 weeks 24 weeks 36 weeks

(27) It can be seen from these evaluation tests that the solid formulations according to the present invention are better significantly than such, which are produced with a different (commonly and widely used) matrix material.